lipopolysaccharide + resatorvid

Lipopolysaccharide + resatorvid is an experimental drug combination used in clinical research to investigate the molecular mechanisms of inflammatory pain and hyperalgesia in humans. Lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria, acts as a potent agonist of Toll-like receptor 4 (TLR4), triggering a localized inflammatory cascade and increasing pain sensitivity when administered intradermally. Resatorvid (also known as TAK-242) is a selective, small-molecule TLR4 antagonist that binds to the intracellular domain of the receptor, specifically at Cys747, thereby inhibiting the protein-protein interactions between TLR4 and its adapter molecules (TIRAP and TRAM). This combination is utilized in a human skin inflammation model, notably in studies led by Stefan Heber, to dissect the contribution of TLR4 signaling to mechanical and acid-induced pain hypersensitivity and to differentiate these pathways from other receptors like RAGE and TRPV1.

Other names

LPS + resatorvidlipopolysaccharide + TAK-242LPS + TAK-242